American Society of Clinical Oncology (ASCO) 2007 Guideline Update: Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer

QualityTool

American Society of Clinical Oncology (ASCO) 2007 Guideline Update: Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer

Description

This table provides the American Society of Clinical Oncology’s previous and current recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.

This table provides the previous (2004) and current (2007) recommendations for the following topics:

  • Is combined androgen blockade better than castration alone?
  • Does early androgen deprivation therapy (ADT) improve outcomes over deferred therapy?
  • Is intermittent ADT better than continuous ADT?

Developer:

American Society of Clinical Oncology

Funding Sources:

American Society of Clinical Oncology

History

Release Date: 2007
Original Summary: August 2007
Last Updated: 04/10/13

Disclaimer: The inclusion of a tool in the Innovations Exchange does not constitute or imply an endorsement by the U.S. Department of Health and Human Services, the Agency for Healthcare Research and Quality or Westat of the tool or of the submitter or developer of the tool. Read more.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.